Publications

Metrics

Google ScholarScopusUCL IrisORCiD

Book chapters 6
Journal articles 76
Total citations 8182
h-index 40
i10-index 65

Last updated September 2020

Book chapters

  1. Biofluid Biomarkers for Huntington’s Disease
    F Rodrigues, L Byrne & E Wild
    In Methods in Molecular Biology: Huntington’s Disease
    eds. Precious, Rosser & Dunnett. Springer, 2018.
  2. Premanifest and Early Huntington’s Disease
    E Wild & S Tabrizi.
    In Huntington’s Disease (Oxford Monographs on Medical Genetics), 3rd ed. Eds G Bates, L Jones & S Tabrizi. Oxford University Press, 2015.
  3. Huntington’s Disease & Other Choreas
    S Haider, E Wild & S Tabrizi.
    In Neurodegeneration, ed. A Schapira. Wiley, 2014.
  4. Huntington’s disease look-alike syndromes
    E Wild & S Tabrizi.
    In Oxford Textbooks in Clinical Neurology: Movement Disorders (2nd edition), ed. D Burn. Oxford University Press, 2013.
  5. Huntington’s Disease
    S Tabrizi & E Wild
    In Neurogenetics: A Guide for Clinicians (2nd edition), ed. N Wood. Cambridge University Press, 2012
  6. Huntington’s Disease and Dementia
    E Wild, N Hobbs & S Henley.
    In Neuroimaging in Dementia (1st edition), ed. F Barkhof, J Valk & N Fox. Springer-Verlag, 2011

PhD Thesis

Identification and evaluation of biomarkers for Huntington’s disease, 2009. University College London.

Peer-reviewed journal articles

    1. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease.
      PLoS One (2020) 15, e0233820.
      Lowe, A. J., Sjodin, S., Rodrigues, F. B., Byrne, L. M., Blennow, K., Tortelli, R., Zetterberg, H. and Wild, E. J.
    2. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.
      Nat Rev Neurol (2020).
      Tabrizi, S. J., Flower, M. D., Ross, C. A. and Wild, E. J.
    3. Characterizing White Matter in Huntington’s Disease.
      Mov Disord Clin Pract (2020) 7, 52-60.
      Gregory, S., Johnson, E., Byrne, L. M., Rodrigues, F. B., Henderson, A., Moss, J., Thomas, D., Zhang, H., De Vita, E., Tabrizi, S. J., Rees, G., Scahill, R. I. and Wild, E. J.
    4. Huntington’s Disease Clinical Trials Corner: April 2020.
      J Huntingtons Dis (2020) 9, 185-197.
      Rodrigues, F. B. and Wild, E. J.
    5. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis.
      Lancet Neurol (2020) 19, 502-512.
      Scahill, R. I., Zeun, P., Osborne-Crowley, K., Johnson, E. B., Gregory, S., Parker, C., Lowe, J., Nair, A., O’Callaghan, C., Langley, C., Papoutsi, M., McColgan, P., Estevez-Fraga, C., Fayer, K., Wellington, H., Rodrigues, F. B., Byrne, L. M., Heselgrave, A., Hyare, H., Sampaio, C., Zetterberg, H., Zhang, H., Wild, E. J., Rees, G., Robbins, T. W., Sahakian, B. J., Langbehn, D. and Tabrizi, S. J.
    6. Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI.
      Eur J Neurosci (2019) 49, 1632-1639.
      Rodrigues, F. B., Byrne, L. M., De Vita, E., Johnson, E. B., Hobbs, N. Z., Thornton, J. S., Scahill, R. I. and Wild, E. J.
    7. Huntington’s Disease Clinical Trials Corner: January 2019.
      J Huntingtons Dis (2019) 8, 115-125.
      Rodrigues, F. B., Quinn, L. and Wild, E. J.
    8. Fluid and imaging biomarkers for Huntington’s disease.
      Mol Cell Neurosci (2019) 97, 67-80.
      Zeun, P., Scahill, R. I., Tabrizi, S. J. and Wild, E. J.
    9. Targeting Huntingtin Expression in Patients with Huntington’s Disease.
      N Engl J Med (2019) 380, 2307-2316.
      Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., Rosser, A., Kordasiewicz, H. B., Czech, C., Swayze, E. E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S. A., Paz, E., Smith, A. V., Bennett, C. F., Lane, R. M. and Phase 1-2a, I.-H. S. S. T.
    10. Comparison of the Huntington’s Disease like 2 and Huntington’s Disease Clinical Phenotypes.
      Mov Disord Clin Pract (2019) 6, 302-311.
      Anderson, D. G., Ferreira-Correia, A., Rodrigues, F. B., Aziz, N. A., Carr, J., Wild, E. J., Margolis, R. L. and Krause, A.
    11. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
      JAMA Neurol (2019).
      Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the, N. F. L. G., Alvarez-Cermeno, J. C., Andreasson, U., Axelsson, M., Backstrom, D. C., Bartos, A., Bjerke, M., Blennow, K., Boxer, A., Brundin, L., Burman, J., Christensen, T., Fialova, L., Forsgren, L., Frederiksen, J. L., Gisslen, M., Gray, E., Gunnarsson, M., Hall, S., Hansson, O., Herbert, M. K., Jakobsson, J., Jessen-Krut, J., Janelidze, S., Johannsson, G., Jonsson, M., Kappos, L., Khademi, M., Khalil, M., Kuhle, J., Landen, M., Leinonen, V., Logroscino, G., Lu, C. H., Lycke, J., Magdalinou, N. K., Malaspina, A., Mattsson, N., Meeter, L. H., Mehta, S. R., Modvig, S., Olsson, T., Paterson, R. W., Perez-Santiago, J., Piehl, F., Pijnenburg, Y. A. L., Pyykko, O. T., Ragnarsson, O., Rojas, J. C., Romme Christensen, J., Sandberg, L., Scherling, C. S., Schott, J. M., Sellebjerg, F. T., Simone, I. L., Skillback, T., Stilund, M., Sundstrom, P., Svenningsson, A., Tortelli, R., Tortorella, C., Trentini, A., Troiano, M., Turner, M. R., van Swieten, J. C., Vagberg, M., Verbeek, M. M., Villar, L. M., Visser, P. J., Wallin, A., Weiss, A., Wikkelso, C. and Wild, E. J.
    12. Huntington’s Disease Clinical Trials Corner: June 2019.
      J Huntingtons Dis (2019) 8, 363-371.
      Rodrigues, F. B., Ferreira, J. J. and Wild, E. J.
    13. One decade ago, one decade ahead in huntington’s disease.
      Mov Disord (2019) 34, 1434-1439.
      Wild, E. J. and Tabrizi, S. J.
    14. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
      Neurology (2018) 90, e717-e723.
      Johnson, E. B., Byrne, L. M., Gregory, S., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A., Zetterberg, H., Tabrizi, S. J., Scahill, R. I., Wild, E. J. and Group, T.-H. S.
    15. Huntington’s Disease Clinical Trials Corner: February 2018.
      J Huntingtons Dis (2018) 7, 89-98.
      Rodrigues, F. B. and Wild, E. J.
    16. Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease.
      Sci Rep (2018) 8, 4260.
      Byrne, L. M., Rodrigues, F. B., Johnson, E. B., De Vita, E., Blennow, K., Scahill, R., Zetterberg, H., Heslegrave, A. and Wild, E. J.
    17. Perinatal insults and neurodevelopmental disorders may impact Huntington’s disease age of diagnosis.
      Parkinsonism Relat Disord (2018) 55, 55-60.
      Barkhuizen, M., Rodrigues, F. B., Anderson, D. G., Winkens, B., Network, R. I. o. t. E. H. s. D., Wild, E. J., Kramer, B. W. and Gavilanes, A. W. D.
    18. Biofluid Biomarkers in Huntington’s Disease.
      Methods Mol Biol (2018) 1780, 329-396.
      Rodrigues, F. B., Byrne, L. M. and Wild, E. J.
    19. Physician perception versus true efficacy of tetrabenazine for Huntington’s disease.
      Curr Med Res Opin (2018) 34, 1537-1538.
      Rodrigues, F. B., Ferreira, J. J. and Wild, E. J.
    20. Huntington’s Disease Clinical Trials Corner: August 2018.
      J Huntingtons Dis (2018) 7, 279-286.
      Rodrigues, F. B. and Wild, E. J.
    21. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease.
      Sci Transl Med (2018) 10.
      Byrne, L. M., Rodrigues, F. B., Johnson, E. B., Wijeratne, P. A., De Vita, E., Alexander, D. C., Palermo, G., Czech, C., Schobel, S., Scahill, R. I., Heslegrave, A., Zetterberg, H. and Wild, E. J.
    22. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.
      Mol Psychiatry (2018).
      Koriath, C., Kenny, J., Adamson, G., Druyeh, R., Taylor, W., Beck, J., Quinn, L., Mok, T. H., Dimitriadis, A., Norsworthy, P., Bass, N., Carter, J., Walker, Z., Kipps, C., Coulthard, E., Polke, J. M., Bernal-Quiros, M., Denning, N., Thomas, R., Raybould, R., Williams, J., Mummery, C. J., Wild, E. J., Houlden, H., Tabrizi, S. J., Rossor, M. N., Hummerich, H., Warren, J. D., Rowe, J. B., Rohrer, J. D., Schott, J. M., Fox, N. C., Collinge, J. and Mead, S.
    23. Ghost Pills: A Case Report.
      Ann Intern Med (2017) 166, 609.
      Salanio, D. M., Taylor, R., Stanton, J. E. D. and Wild, E. J.
    24. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis.
      Lancet Neurol (2017) 16, 601-609.
      Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D. and Wild, E. J.
    25. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: Twins or Distant Cousins?
      Mov Disord Clin Pract (2017) 4, 582-585.
      Rodrigues, F. B., Duarte, G. S., Costa, J., Ferreira, J. J. and Wild, E. J.
    26. Therapies targeting DNA and RNA in Huntington’s disease.
      Lancet Neurol (2017) 16, 837-847.
      Wild, E. J. and Tabrizi, S. J.
    27. Clinical Trials Corner: September 2017.
      J Huntingtons Dis (2017) 6, 255-263.
      Rodrigues, F. B. and Wild, E. J.
    28. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice.
      Sci Rep (2017) 7, 14114.
      Soylu-Kucharz, R., Sandelius, A., Sjogren, M., Blennow, K., Wild, E. J., Zetterberg, H. and Bjorkqvist, M.
    29. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
      J Huntingtons Dis (2017) 6, 349-361.
      Fodale, V., Boggio, R., Daldin, M., Cariulo, C., Spiezia, M. C., Byrne, L. M., Leavitt, B. R., Wild, E. J., Macdonald, D., Weiss, A. and Bresciani, A.
    30. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”.
      J Clin Mov Disord (2017) 4, 19.
      Rodrigues, F. B., Duarte, G. S., Costa, J., Ferreira, J. J. and Wild, E. J.
    31. Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays.
      PLoS One (2017) 12, e0189891.
      Hensman Moss, D. J., Robertson, N., Farmer, R., Scahill, R. I., Haider, S., Tessari, M. A., Flynn, G., Fischer, D. F., Wild, E. J., Macdonald, D. and Tabrizi, S. J.
    32. Cerebrospinal Fluid Biomarkers for Huntington’s Disease.
      J Huntingtons Dis (2016) 5, 1-13.
      Byrne, L. M. and Wild, E. J.
    33. Psychogenic non-epileptic seizures in early Huntington’s disease.
      Pract Neurol (2016) 16, 452-454.
      Rodrigues, F. B. and Wild, E. J.
    34. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease.
      J Neurochem (2016) 139, 22-25.
      Rodrigues, F. B., Byrne, L., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H. and Wild, E. J.
    35. George Huntington: a legacy of inquiry, empathy and hope.
      Brain (2016) 139, 2326-2333.
      Wexler, A., Wild, E. J. and Tabrizi, S. J.
    36. Huntington’s Disease: The Most Curable Incurable Brain Disorder?
      EBioMedicine (2016) 8, 3-4.
      Wild, E. J.
    37. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease.
      PLoS One (2016) 11, e0163479.
      Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H. and Wild, E. J.
    38. Huntington disease.
      Nat Rev Dis Primers (2015) 1, 15005.
      Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., Wild, E. J. and Tabrizi, S. J.
    39. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients.
      J Clin Invest (2015) 125, 1979-1986.
      Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., Macdonald, D. and Weiss, A.
    40. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.
      Neurology (2014) 82, 292-299.
      Hensman Moss, D. J., Poulter, M., Beck, J., Hehir, J., Polke, J. M., Campbell, T., Adamson, G., Mudanohwo, E., McColgan, P., Haworth, A., Wild, E. J., Sweeney, M. G., Houlden, H., Mead, S. and Tabrizi, S. J.
    41. Huntington disease: natural history, biomarkers and prospects for therapeutics.
      Nat Rev Neurol (2014) 10, 204-216.
      Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., Reilmann, R., Unschuld, P. G., Wexler, A., Margolis, R. L. and Tabrizi, S. J.
    42. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline?
      Mov Disord (2014) 29, 1434-1445.
      Wild, E. J. and Tabrizi, S. J.
    43. JAK/STAT Signalling in Huntington’s Disease Immune Cells.
      PLoS Curr (2013) 5.
      Trager, U., Magnusson, A., Lahiri Swales, N., Wild, E., North, J., Lowdell, M. and Bjorkqvist, M.
    44. HDBuzz: empowering patients through accessible education.
      Trends Mol Med (2012) 18, 1-3.
      Wild, E. J. and Carroll, J. B.
    45. Huntington’s disease: fighting on many fronts.
      Brain (2012) 135, 998-1001.
      Andre, R., Wild, E. J. and Tabrizi, S. J.
    46. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression.
      J Clin Invest (2012) 122, 3731-3736.
      Weiss, A., Trager, U., Wild, E. J., Grueninger, S., Farmer, R., Landles, C., Scahill, R. I., Lahiri, N., Haider, S., Macdonald, D., Frost, C., Bates, G. P., Bilbe, G., Kuhn, R., Andre, R. and Tabrizi, S. J.
    47. Biomarkers for Huntington’s disease: an update.
      Expert Opin Med Diagn (2012) 6, 371-375.
      Scahill, R. I., Wild, E. J. and Tabrizi, S. J.
    48. Abnormal peripheral chemokine profile in Huntington’s disease.
      PLoS Curr (2011) 3, RRN1231.
      Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M., Tabrizi, S. J. and Bjorkqvist, M.
    49. Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY.
      J Neurol Neurosurg Psychiatry (2011) 82, 1409-1412.
      Orth, M., European Huntington’s Disease, N., Handley, O. J., Schwenke, C., Dunnett, S., Wild, E. J., Tabrizi, S. J. and Landwehrmeyer, G. B.
    50. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
      Hum Mol Genet (2011) 20, 1937-1951.
      Munsie, L., Caron, N., Atwal, R. S., Marsden, I., Wild, E. J., Bamburg, J. R., Tabrizi, S. J. and Truant, R.
    51. Brain-derived neurotrophic factor in patients with Huntington’s disease.
      PLoS One (2011) 6, e22966.
      Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Levi, A. C., Tabrizi, S. J., Di Donato, S. and Cattaneo, E.
    52. Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY.
      PLoS Curr (2010) 2, RRN1184.
      Orth, M., Handley, O. J., Schwenke, C., Dunnett, S. B., Craufurd, D., Ho, A. K., Wild, E., Tabrizi, S. J., Landwehrmeyer, G. B. and Investigators of the European Huntington’s Disease, N.
    53. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study.
      J Neurol Neurosurg Psychiatry (2010) 81, 756-763.
      Hobbs, N. Z., Henley, S. M., Ridgway, G. R., Wild, E. J., Barker, R. A., Scahill, R. I., Barnes, J., Fox, N. C. and Tabrizi, S. J.
    54. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.
      AJNR Am J Neuroradiol (2010) 31, 1036-1041.
      Hobbs, N. Z., Barnes, J., Frost, C., Henley, S. M., Wild, E. J., Macdonald, K., Barker, R. A., Scahill, R. I., Fox, N. C. and Tabrizi, S. J.
    55. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease.
      Mov Disord (2010) 25, 888-895.
      Wild, E. J., Henley, S. M., Hobbs, N. Z., Frost, C., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
    56. Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s disease.
      Mov Disord (2009) 24, 932-936.
      Henley, S. M., Wild, E. J., Hobbs, N. Z., Frost, C., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
    57. Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease.
      J Neurol (2009) 256, 203-212.
      Henley, S. M., Wild, E. J., Hobbs, N. Z., Scahill, R. I., Ridgway, G. R., Macmanus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
    58. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease.
      Neuroimage (2009) 47, 1659-1665.
      Hobbs, N. Z., Henley, S. M., Wild, E. J., Leung, K. K., Frost, C., Barker, R. A., Scahill, R. I., Barnes, J., Tabrizi, S. J. and Fox, N. C.
    59. Harnessing immune alterations in neurodegenerative diseases.
      Neuron (2009) 64, 21-24.
      Bjorkqvist, M., Wild, E. J. and Tabrizi, S. J.
    60. Serial volumetric MRI in Parkinsonian disorders.
      Mov Disord (2009) 24 Suppl 2, S691-698.
      Wild, E. J. and Fox, N. C.
    61. Rapid eye movement sleep disturbances in Huntington disease.
      Arch Neurol (2008) 65, 482-488.
      Arnulf, I., Nielsen, J., Lohmann, E., Schiefer, J., Wild, E., Jennum, P., Konofal, E., Walker, M., Oudiette, D., Tabrizi, S. and Durr, A.
    62. Immune markers for Huntington’s disease?
      Expert Rev Neurother (2008) 8, 1779-1781.
      Wild, E., Bjorkqvist, M. and Tabrizi, S. J.
    63. Biomarkers for Huntington’s disease.
      Expert Opin Med Diagn (2008) 2, 47-62.
      Wild, E. J. and Tabrizi, S. J.
    64. Huntington’s disease phenocopies are clinically and genetically heterogeneous.
      Mov Disord (2008) 23, 716-720.
      Wild, E. J., Mudanohwo, E. E., Sweeney, M. G., Schneider, S. A., Beck, J., Bhatia, K. P., Rossor, M. N., Davis, M. B. and Tabrizi, S. J.
    65. Defective emotion recognition in early HD is neuropsychologically and anatomically generic.
      Neuropsychologia (2008) 46, 2152-2160.
      Henley, S. M., Wild, E. J., Hobbs, N. Z., Warren, J. D., Frost, C., Scahill, R. I., Ridgway, G. R., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
    66. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease.
      J Exp Med (2008) 205, 1869-1877.
      Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., Magnusson, A., Woodman, B., Landles, C., Pouladi, M. A., Hayden, M. R., Khalili-Shirazi, A., Lowdell, M. W., Brundin, P., Bates, G. P., Leavitt, B. R., Moller, T. and Tabrizi, S. J.
    67. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease.
      Brain (2008) 131, 2851-2859.
      Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M., Hobbs, N. Z., Mandelli, M. L., Grisoli, M., Bjorkhem, I., Cattaneo, E. and Di Donato, S.
    68. Plasma neurofilament heavy chain levels in Huntington’s disease.
      Neurosci Lett (2007) 417, 231-233.
      Wild, E. J., Petzold, A., Keir, G. and Tabrizi, S. J.
    69. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates.
      J Proteome Res (2007) 6, 2833-2840.
      Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Bjorkqvist, M., Petersen, A., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., Leavitt, B. R., Keir, G., Ward, M. and Tabrizi, S. J.
    70. Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood.
      Proc Natl Acad Sci U S A (2007) 104, 14424-14429.
      Runne, H., Kuhn, A., Wild, E. J., Pratyaksha, W., Kristiansen, M., Isaacs, J. D., Regulier, E., Delorenzi, M., Tabrizi, S. J. and Luthi-Carter, R.
    71. Huntington’s disease phenocopy syndromes.
      Curr Opin Neurol (2007) 20, 681-687.
      Wild, E. J. and Tabrizi, S. J.
    72. The differential diagnosis of chorea.
      Pract Neurol (2007) 7, 360-373.
      Wild, E. J. and Tabrizi, S. J.
    73. Vasculitic presentation of staphylococcal meningitis.
      Arch Neurol (2007) 64, 1788-1789.
      Bentley, P., Qadri, F., Wild, E. J., Hirsch, N. P. and Howard, R. S.
    74. Predict-HD and the future of therapeutic trials.
      Lancet Neurol (2006) 5, 724-725.
      Wild, E. J. and Tabrizi, S. J.
    75. Deja vu in neurology.
      J Neurol (2005) 252, 1-7.
      Wild, E.
    76. Thyrotoxic periodic paralysis in a Maori patient.
      N Z Med J (2004) 117, U1204.
      Wild, E.